Avatrombopag Usage in NSAA
Study Details
Study Description
Brief Summary
This is a multicenter, open-label, prospective one arm study to explore the efficacy and safety of Avatrombopag in non-severe aplastic anemia. Patients meeting the inclusion and exclusion criteria would be recruited. Treatment of Avatrombopag would be started with 20mg/day. The dosage would be increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The dosage could range from 20mg/week to 60mg/day. All patients would receive treatment for at least 6 months except that the platelet <20×10e9/L at the dosage of 60mg/day for 4 weeks or the platelet ≥200×10e9/L at the dosage of 20mg/week for 2 weeks. The hematological response rate and safety will be recorded and compared at every month after starting the study treatment. The patients would be followed up for at least 6 months.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Avatrombopag treatment group Avatrombopag would be started with 20mg/day. The dosage would be increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L. The dosage could range from 20mg/week to 60mg/day. |
Drug: Avatrombopag 20 MG
Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
|
Outcome Measures
Primary Outcome Measures
- ORR at 6 Months [6 months]
Overall Response Rate (ORR) Defined as the Number of Participants Who Met the Criteria of Either Complete Response (CR) or Partial Response (PR) at 6 months
Secondary Outcome Measures
- ORR at 3 Months [3 months]
ORR will be calculated after 3 months of treatment by measuring platelet, reticulocyte, neutrophil and transfusion independence.
- Percentage of patients with clonal evolution at 6 months [6 months]
Percentage of patients with clonal evolution would be evaluated by bone marrow biopsy at 6 months follow up.
- percentage of side effects at 6 months [6 months]
percentage of side effects would be recorded during the study and be calculated according to CTCAE 5.0 at 6 months
- Total volume of Platelet Transfusions [1 month]
Total volume of Platelet Transfusions
- Total volume of Red Blood Cells Transfusions [1 month]
Total volume of Red Blood Cells Transfusions
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients diagnosed to be non-severe aplastic anemia
-
Patients have at least one of the followings: ①absolute neutrophil count < 1.5×109/L, ②platelet count < 30×109/L, ③ hemoglobin level < 100g/L
-
Patients have no response or relapsed following at least one treatment course in a period time of > 6 months of immunosuppression containing CsA or CsA+anti-thymocyte globulin (ATG);
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
-
Patients able to understand and comply with protocol requirements and instructions and have signed and dated informed consent.
Exclusion Criteria:
-
Congenital aplastic anemia;
-
Presence of chromosomal aberration;
-
Evidence of a clonal hematologic bone marrow disorder (MDS, AML) on cytogenetics;
-
Presence with PNH clone ≥50%;
-
Patients received HSCT before;
-
Uncontrolled infection or bleeding with standard treatment;
-
Allergic to Avatrombopag or accessories;
-
HIV, HCV or HBV active infection or liver cirrhosis or portal hypertension;
-
Patient with QTcF (Fridericia's QT correction formula) at screening <450 msec, or<480 msec with bundle branch block, as determined via the mean of a triplicate ECG and assessed at site, unstable angina pectoris, uncontrolled hypertension(>180/100mmHg)，pulmonary artery hypertension;
-
Have any concomitant malignancies within 5 years expect for local basal cell carcinoma of the skin;
-
Past history of thromboembolic event, heart attack or stroke (including anti-phospholipid antibody syndrome) and current use of anticoagulants;
-
Pregnant or nursing (lactating) woman;
-
Have attended other clinical trials within 3 months;
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Peking Union Medical College Hospital | Beijing | China | 100730 |
Sponsors and Collaborators
- Peking Union Medical College Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Avatrombopag-1